AI-generated · cited to primary sources · not investment advice · How we research
Indegene
Our verdict on Indegene isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The delivery headcount with healthcare expertise reached 24.8%, slightly exceeding the upper bound of the previously guided range. (3 exceeded, 2 met across 5 tracked commitments)
“But we certainly are looking forward to a growth rate, which is higher than what we saw in the past year and even the start of this year.”
Revenue per employee crossed the $70K annual mark, which management claims is the highest in the industry, driven by AI-led productivity scaling. (1 exceeded, 1 met across 2 tracked commitments)
“But consistently over the past 4, 5 years that has been in the vicinity of 2% of our revenue would be in that 1.7%, 1.8% going towards 2%, but would not be materially different from our plan going forward.”
See the full cited Management analysis of Indegene
How durable is the business?
The segment remains the primary revenue engine, growing 5.1% sequentially in Q4 FY25, though its total revenue share has slightly moderated from 71% to approximately 56% as other segments grew faster. (5 expanding)
“Core segments (ECS & EMS) grew 5.1% sequentially... ECS [Q4 FY25] 4,225”
While the company lost volume in two major accounts, they successfully grew their 'USD 1 million plus' client base and won a significant USD 5 million plus ACV deal with a Top 10 EU pharma company, indicating continued stickiness in large-scale enterprise deals. (5 expanding)
“56% (63%) Revenue from Top 20 Global Biopharma* Companies; 52 (40) Clients with $1 Million+ Revenue”
See the full cited Business Model analysis of Indegene
Where does growth come from?
Revenue from the Medical Devices segment is growing at an explosive rate, more than doubling YoY and showing strong sequential momentum. (1 accelerating across 1 signal)
“Medical Devices... YoY Growth 112.2%”
Revenue growth is accelerating significantly, reaching its first $100 million+ quarter with a 30.8% YoY increase compared to 7.0% in the prior year period. (1 accelerating across 1 signal)
“We delivered a standout Q3 FY26, with revenue growing over 30% YoY and 17% sequentially, marking it the first $100 million+ revenue quarter.”
See the full cited Future Growth analysis of Indegene
What could break the thesis?
The risk is intensifying as North American revenue share increased from 69.3% in Q3 to 71.9% in Q4, further concentrating geographic risk. (1 intensifying, 4 stable, 2 high-severity)
“Revenue by customer geography (in %)... North America 71.8%”
The risk is intensifying in terms of immediate financial impact as M&A expenses surged 507% QoQ (from 7 Mn to 42 Mn). However, management has integrated two new entities (BioPharm and WARN & Co.) to align with future growth. (2 intensifying, 2 emerging, 1 easing, 1 high-severity)
“Higher Depreciation and Amortization as non-cash charges, increased from INR234 million in Quarter 2 to INR396 million in Quarter 3, reflecting amortization of the intangibles from the recent acquisition... Both these impacted about 205 basis points at a PBT level and 156 basis points at the PAT level.”
See the full cited Risk analysis of Indegene
Read the full thesis on Indegene
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.